StocksFundsScreenerSectorsWatchlists
RAPT

RAPT - RAPT Therapeutics Inc Stock Price, Fair Value and News

8.79USD-0.14 (-1.57%)Delayed as of 28 Mar 2024, 11:04 am ET

Market Summary

RAPT
USD8.79-0.14
Delayedas of 28 Mar 2024, 11:04 am
-1.57%

RAPT Stock Price

View Fullscreen

RAPT RSI Chart

RAPT Valuation

Market Cap

310.7M

Price/Earnings (Trailing)

-2.66

Price/Sales (Trailing)

211.48

EV/EBITDA

-4.05

Price/Free Cashflow

-3.17

RAPT Price/Sales (Trailing)

RAPT Profitability

EBT Margin

-4532.02%

Return on Equity

-79.44%

Return on Assets

-67.39%

Free Cashflow Yield

-31.59%

RAPT Fundamentals

RAPT Revenue

Revenue (TTM)

1.5M

RAPT Earnings

Earnings (TTM)

-116.8M

Earnings Growth (Yr)

-34.53%

Earnings Growth (Qtr)

1.58%

Breaking Down RAPT Revenue

52 Week Range

8.7125.78
(Low)(High)

Last 7 days

-1.6%

Last 30 days

-67.9%

Last 90 days

-64.7%

Trailing 12 Months

-65.7%

How does RAPT drawdown profile look like?

RAPT Financial Health

Current Ratio

7.41

RAPT Investor Care

Shares Dilution (1Y)

1.49%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20223.2M3.2M2.3M1.5M
20215.3M4.9M4.4M3.8M
20200005.0M

Tracking the Latest Insider Buys and Sells of RAPT Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 05, 2024
brockstedt dirk g.
sold
-20,456
22.78
-898
chief scientific officer
Dec 29, 2023
brockstedt dirk g.
acquired
49,440
6.18
8,000
chief scientific officer
Dec 21, 2023
ho william
sold
-54,200
21.68
-2,500
chief medical officer
Nov 28, 2023
ho william
sold
-20,580
13.72
-1,500
chief medical officer
Oct 03, 2023
ho william
sold
-39,425
15.77
-2,500
chief medical officer
Aug 18, 2023
ho william
sold
-47,300
18.92
-2,500
chief medical officer
Jul 28, 2023
ho william
acquired
5,520
12.00
460
chief medical officer
Jun 23, 2023
ho william
acquired
11,040
12.00
920
chief medical officer
Apr 19, 2023
ho william
sold
-94,400
18.88
-5,000
chief medical officer
Apr 13, 2023
ho william
acquired
5,520
12.00
460
chief medical officer

1–10 of 50

Which funds bought or sold RAPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 18, 2024
KINGDON CAPITAL MANAGEMENT, L.L.C.
added
139
34,608,800
48,001,700
3.01%
Mar 11, 2024
VANGUARD GROUP INC
added
1.63
17,469,800
51,097,100
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
120
6,797,200
9,755,070
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.41
119,828
364,823
-%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
added
11.42
21,256,400
53,177,800
1.19%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-33.47
-2,000
508,000
0.04%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-3.57
25,995,000
84,828,000
0.01%
Feb 15, 2024
BARCLAYS PLC
added
46.27
1,057,000
1,949,000
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
50.00
50.00
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
79.4
1,190,330
1,897,840
-%

1–10 of 44

Are Funds Buying or Selling RAPT?

Are funds buying RAPT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RAPT
No. of Funds

Unveiling RAPT Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
deep track capital, lp
5.22%
1,793,966
SC 13G/A
Feb 14, 2024
price t rowe associates inc /md/
9.9%
3,413,552
SC 13G/A
Feb 14, 2024
redmile group, llc
9.9%
3,776,847
SC 13G/A
Feb 14, 2024
perceptive advisors llc
6.2%
2,139,950
SC 13G/A
Feb 13, 2024
vanguard group inc
5.98%
2,056,221
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 26, 2024
blackrock inc.
7.1%
2,453,049
SC 13G/A
Jan 23, 2024
state street corp
4.23%
1,454,556
SC 13G/A
Oct 23, 2023
deep track capital, lp
5.80%
1,991,403
SC 13G
Jun 12, 2023
price t rowe associates inc /md/
10.4%
3,556,462
SC 13G/A

Recent SEC filings of RAPT Therapeutics Inc

View All Filings
Date Filed Form Type Document
Mar 07, 2024
10-K
Annual Report
Mar 07, 2024
8-K
Current Report
Mar 07, 2024
S-8
Employee Benefits Plan
Feb 22, 2024
8-K
Current Report
Feb 20, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G
Major Ownership Report

Peers (Alternatives to RAPT Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

RAPT Therapeutics Inc News

Latest updates
Defense World • 6 hours ago
Yahoo Finance • 22 Mar 2024 • 09:39 am
Markets Insider • 21 Feb 2024 • 08:00 am
MarketWatch • 20 Feb 2024 • 08:00 am
Investor's Business Daily • 20 Feb 2024 • 08:00 am

RAPT Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Revenue----886,000641,000756,000966,000869,0001,222,0001,302,0001,528,0001,277,000935,000
Operating Expenses36.0%33,217,00024,431,00021,678,00019,795,00021,418,00018,790,00019,499,00016,950,00017,783,00014,387,00016,109,00013,788,00013,972,000
  S&GA Expenses29.7%6,453,0004,977,0005,079,0005,436,0004,748,0004,491,0003,774,0003,760,0004,012,0003,483,0003,197,0002,802,0003,289,000
  R&D Expenses37.6%26,764,00019,454,00016,599,00014,359,00016,670,00014,299,00015,725,00013,190,00013,771,00010,904,00012,912,00010,986,00010,683,000
EBITDA Margin0.3%-44.53-44.68-29.87-21.02-21.13-17.90-14.43-11.89-10.19----
Income Taxes----------199,000287,000267,000237,000
Earnings Before Taxes-------17,929,000-18,651,000-16,110,000-16,514,000-12,536,000-14,344,000-12,120,000-12,902,000
EBT Margin0%-45.32-45.32-30.31-21.30-21.41-18.15-14.64-12.09-10.42----
Net Income-34.5%-30,876,000-22,951,000-21,235,000-19,184,000-20,468,000-17,929,000-18,651,000-16,110,000-16,514,000-12,735,000-14,631,000-12,387,000-13,139,000
Net Income Margin-39.3%-76.49-54.90-34.52-23.46-22.64-18.15-14.68-12.19-10.56----
Free Cashflow-21.5%-27,821,000-22,898,000-17,230,000-15,761,000-15,727,000-21,075,000-12,589,000-13,980,000-14,137,000----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-13.2%17320022124826620922218819921723110611912914015185.0058.0062.0066.0070.00
  Current Assets-13.5%16218720723525319821017619321422810311612613614781.0051.00--65.00
    Cash Equivalents-12.3%47.0054.0050.0046.0039.0028.0057.0032.0024.0060.0086.0025.0025.0020.0029.0092.0077.0048.00--64.00
  Net PPE-9.5%2.003.003.003.003.003.003.003.003.003.003.003.003.003.003.004.004.004.00--4.00
Liabilities-2.3%26.0027.0021.0028.0021.0020.0020.0020.0012.0016.0014.0014.0015.00---11.00----
  Current Liabilities-0.1%22.0022.0015.0022.0014.0014.0013.0012.0010.0013.0010.0011.0012.0016.0013.0013.009.005.00--5.00
Shareholder's Equity-14.9%14717320022024518920216818620221892.0010411012313273.00----
  Retained Earnings-6.8%-484-453-422-397-367-344-323-304-284-266-247-231-214-202-187-175-161-148---118
  Additional Paid-In Capital0.8%63262762261761353552747347146846532331931231030723524.00--22.00
Shares Outstanding-100.0%-38.0038.0038.0034.0034.0030.0030.0030.0027.0025.0025.00---------
Float-------319---622---437------
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-26.8%-27,754-21,884-28,808-18,602-22,849-17,149-15,195-15,578-20,681-12,519-13,916-13,910-15,366-9,953-6,427-8,745-5,688-12,139-9,013-8,634-
  Share Based Compensation2.3%4,4294,3294,2394,0943,0252,8652,6722,7022,0862,2912,8882,6872,5582,0052,0352,088896431347377-
Cashflow From Investing-19.8%20,63925,74932,43725,308-41,270-17,599-10,45823,837-15,892-14,174-63,69212,41115,4951,060-57,009-46,98120.00-76.00-368-419-
Cashflow From Financing332.1%45810676711675,3595,25150,438132601472139,1081,3014,56016586469,87234,7416637,4857,013-
  Buy Backs-------------------65.00109-

RAPT Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]  
Revenue$ 0$ 1,527
Operating expenses:  
Research and development101,00267,082
General and administrative26,06020,240
Total operating expenses127,06287,322
Loss from operations(127,062)(85,795)
Other income, net10,2641,957
Net loss(116,798)(83,838)
Other comprehensive income (loss):  
Foreign currency translation gain (loss)(655)627
Unrealized gain (loss) on marketable securities784(447)
Total comprehensive loss$ (116,669)$ (83,658)
Net loss per share, basic$ (3.05)$ (2.58)
Net loss per share, diluted$ (3.05)$ (2.58)
Weighted average number of shares used in computing net loss per share, basic38,338,16132,540,406
Weighted average number of shares used in computing net loss per share, diluted38,338,16132,540,406

RAPT Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 47,478$ 38,946
Marketable securities111,384210,122
Prepaid expenses and other current assets2,9203,626
Total current assets161,782252,694
Property and equipment, net2,4482,539
Operating lease right-of-use assets5,2286,940
Other assets3,8714,036
Total assets173,329266,209
Current liabilities:  
Accounts payable5,1763,365
Accrued expenses14,1038,656
Operating lease liabilities, current2,4482,171
Other current liabilities10932
Total current liabilities21,83614,224
Operating lease liabilities, non-current4,4586,819
Total liabilities26,29421,043
Commitments (see note 6)
Stockholders' equity:  
Preferred stock, $0.0001 par value: 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022
Common stock, $0.0001 par value; 500,000,000 shares authorized; 34,398,312 and 34,254,314 shares issued and outstanding at December 31, 2023 and 2022, respectively33
Additional paid-in capital631,611613,073
Accumulated other comprehensive gain (loss)103(26)
Accumulated deficit(484,682)(367,884)
Total stockholders' equity147,035245,166
Total liabilities and stockholders' equity$ 173,329$ 266,209
RAPT
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEwww.rapt.com
 EMPLOYEES122

RAPT Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for RAPT Therapeutics Inc? What does RAPT stand for in stocks?

RAPT is the stock ticker symbol of RAPT Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of RAPT Therapeutics Inc (RAPT)?

As of Wed Mar 27 2024, market cap of RAPT Therapeutics Inc is 310.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RAPT stock?

You can check RAPT's fair value in chart for subscribers.

What is the fair value of RAPT stock?

You can check RAPT's fair value in chart for subscribers. The fair value of RAPT Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of RAPT Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RAPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is RAPT Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RAPT is over valued or under valued. Whether RAPT Therapeutics Inc is cheap or expensive depends on the assumptions which impact RAPT Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RAPT.

What is RAPT Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, RAPT's PE ratio (Price to Earnings) is -2.66 and Price to Sales (PS) ratio is 211.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RAPT PE ratio will change depending on the future growth rate expectations of investors.